Volume 4 Supplement 1
Association for Immunotherapy of Cancer: Cancer Immunotherapy - 2nd Annual Meeting
Meeting abstracts
Association for Immunotherapy of Cancer: Cancer Immunotherapy - 2nd Annual Meeting. Go to conference site.
Mainz, Germany6-7 May 2004
Page 1 of 2
-
Citation: Cancer Cell International 2004 4(Suppl 1):S1
-
Antibody-based immunoreceptors: the impact of signalling domain, binding affinity and costimulation
Citation: Cancer Cell International 2004 4(Suppl 1):S2 -
Tolerability and efficacy of the trifunctional antibody removab® (anti-EpCAM x anti-CD3) in patients with malignant ascites due to ovarian cancer: Results of a phase I/II study
Citation: Cancer Cell International 2004 4(Suppl 1):S3 -
HLA DR-directed bispecific single-chain Fv antibodies for lymphoma therapy
Citation: Cancer Cell International 2004 4(Suppl 1):S4 -
Increased frequency of CTLA4+ TGFβ+ CD4+ CD25+ T cells in peripheral blood of patients with chronic lymphatic leukemia and multiple myeloma
Citation: Cancer Cell International 2004 4(Suppl 1):S5 -
MMP-7 inhibits CTL – tumor cell interaction
Citation: Cancer Cell International 2004 4(Suppl 1):S6 -
Genetically modified natural killer cells specifically recognizing the tumor-associated antigens ErbB2/HER2 and EpCAM
Citation: Cancer Cell International 2004 4(Suppl 1):S7 -
Rapid functional exhaustion and deletion of cytotoxic T lymphocytes following immunization with recombinant adenovirus
Citation: Cancer Cell International 2004 4(Suppl 1):S8 -
High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma
Citation: Cancer Cell International 2004 4(Suppl 1):S9 -
Adoptive T cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma: a phase I clinical study
Citation: Cancer Cell International 2004 4(Suppl 1):S10 -
Large scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
Citation: Cancer Cell International 2004 4(Suppl 1):S11 -
Reversible HLA multimers (streptamers) for isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens
Citation: Cancer Cell International 2004 4(Suppl 1):S12 -
Therapeutic efficacy of RAGE-1 and MAGE-9 peptide specific cytotoxic T cell clones in renal cell carcinoma
Citation: Cancer Cell International 2004 4(Suppl 1):S13 -
The role of glycosylation as a modulator for signalling strength in T cells
Citation: Cancer Cell International 2004 4(Suppl 1):S14 -
Migration of dendritic cells to regional lymph nodes in a vaccination trial
Citation: Cancer Cell International 2004 4(Suppl 1):S15 -
Transitory response to vaccination with PSCA-/PSA-peptide loaded, autologous dendritic cells in patients with metastatic, hormone-refractory prostate cancer
Citation: Cancer Cell International 2004 4(Suppl 1):S16 -
Vaccination with WT1 induces high frequency memory and effector T cells in peripheral blood and bone marrow associated with complete remission of recurrent AML
Citation: Cancer Cell International 2004 4(Suppl 1):S17 -
LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers
Citation: Cancer Cell International 2004 4(Suppl 1):S18 -
Tumor vaccination after allogeneic bone marrow cell reconstitution of the non-myeloablatively conditioned tumor-bearing murine host
Citation: Cancer Cell International 2004 4(Suppl 1):S19 -
Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation™)
Citation: Cancer Cell International 2004 4(Suppl 1):S20 -
Proteasome inhibition enhances HLA-class-II antibody-dependent polymorphonuclear cell mediated cytotoxicity against B-cell lymphoma
Citation: Cancer Cell International 2004 4(Suppl 1):S21 -
Increased effector functions of a monoclonal antibody by glycoform engineering
Citation: Cancer Cell International 2004 4(Suppl 1):S22 -
Inhibition of signaling via erbB-receptors by antibodies that target the Lewis Y-antigen
Citation: Cancer Cell International 2004 4(Suppl 1):S23 -
Release of iC3b from apoptotic pancreatic tumor cells induces tolerance by binding to immature dendritic cells
Citation: Cancer Cell International 2004 4(Suppl 1):S24 -
Bisphosphonic acid acts as Gamma/Delta T cell activating antigen and has direct cytotoxic activity against pancreatic carcinoma cells
Citation: Cancer Cell International 2004 4(Suppl 1):S25 -
Regulation of p53 tumor specific immune responses in colorectal cancer patients
Citation: Cancer Cell International 2004 4(Suppl 1):S26 -
Assessment of genes associated with immune activation and regulation in pancreatic cancer patients
Citation: Cancer Cell International 2004 4(Suppl 1):S27 -
Modulation of tumour directed B cell responses by NK cells
Citation: Cancer Cell International 2004 4(Suppl 1):S28 -
NFκB activation and TGFβ loss signatures are prominent ex vivo responses of peripheral blood mononuclear cells
Citation: Cancer Cell International 2004 4(Suppl 1):S29 -
Enrichment of functional CD8 memory T cells specific for MUC1 in Bone Marrow of Multiple Myeloma Patients
Citation: Cancer Cell International 2004 4(Suppl 1):S30 -
Isolated γδ T cells express natural cytotoxicity receptors
Citation: Cancer Cell International 2004 4(Suppl 1):S31 -
The kinetics of accumulation of adoptively transferred ovalbumin-specific T cells in a transgenic, ovalbumin-expressing murine tumor
Citation: Cancer Cell International 2004 4(Suppl 1):S32 -
Tumor-specific murine T cell receptors displace endogenous TCRs in human T cells
Citation: Cancer Cell International 2004 4(Suppl 1):S33 -
Induction of leukemia reactive, allogeneic donor lymphocytes
Citation: Cancer Cell International 2004 4(Suppl 1):S34 -
Identification of a melanoma-associated chondroitin sulfate proteoglycan (MCSP) peptide recognized by CD4+ T lymphocytes on human melanoma cells
Citation: Cancer Cell International 2004 4(Suppl 1):S35 -
Chimeric carrier proteins for targeted delivery of tumor antigens to professional antigen presenting cells
Citation: Cancer Cell International 2004 4(Suppl 1):S36 -
Particulate antigenic structures: highly immunogenic carriers for T cell epitopes derived from tumour antigens
Citation: Cancer Cell International 2004 4(Suppl 1):S37 -
Development, monitoring and first immunological results of a phase I/II vaccination trial using genetically modified allogeneic breast cancer cells
Citation: Cancer Cell International 2004 4(Suppl 1):S38 -
Dendritic cell-based immunotherapy of hormone refractory prostate carcinoma (HRPCa) – a pilot trial
Citation: Cancer Cell International 2004 4(Suppl 1):S39 -
The European Searchable Tumour Cell and Databank, ESTDAB, as a tool for research in cancer immunology
Citation: Cancer Cell International 2004 4(Suppl 1):S40 -
Efficient in vitro expression of human reverse transcriptase (hTERT) in dendritic cells of lung cancer patients using RNA electrotransfection
Citation: Cancer Cell International 2004 4(Suppl 1):S41 -
Parvovirus H1-induced tumor cell death enhances human immune response via crosspresentation of dendritic cells
Citation: Cancer Cell International 2004 4(Suppl 1):S42 -
Optimizing the antigen loading of dendritic cells with exogenous peptides
Citation: Cancer Cell International 2004 4(Suppl 1):S43 -
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
Citation: Cancer Cell International 2004 4(Suppl 1):S44 -
Survival and homing of ex vivo expanded donor derived dendritic cells after allogeneic BMT
Citation: Cancer Cell International 2004 4(Suppl 1):S45 -
PBMCs transfected with RNActive stimulate specific T-cells
Citation: Cancer Cell International 2004 4(Suppl 1):S46 -
Addition of histamine to IL-2 treatment augments T1 cell-function in melanoma patients in vivo: results from a randomized clinical trial of IL-2 with or without histamine (MP 104)
Citation: Cancer Cell International 2004 4(Suppl 1):S47 -
Peptide vaccination induces specific effector and memory T cells but fails to enhance preexisting T cell immunity
Citation: Cancer Cell International 2004 4(Suppl 1):S48 -
Biological characterization of CD40-activated B cells as a prerequisite for their use as cellular adjuvant in cancer vaccines
Citation: Cancer Cell International 2004 4(Suppl 1):S49 -
Identification of a novel epitope derived from the cancer-germline antigen, HAGE, displaying both in-vitro and in-vivo immunogenicity
Citation: Cancer Cell International 2004 4(Suppl 1):S50
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 5.3
5-year Journal Impact Factor: 5.0
Source Normalized Impact per Paper (SNIP): 0.920
SCImago Journal Rank (SJR): 1.257Speed 2023
Submission to first editorial decision (median days): 15
Submission to acceptance (median days): 110Usage 2023
Downloads: 2,067,719
Altmetric mentions: 1,052
On the blog
-
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).